Response to histone deacetylase inhibition of novel PML/RARα mutants detected in retinoic acid–resistant APL cells
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Resistance to all-trans retinoic acid (ATRA) remains a clinical problem in the treatment of acute promyelocytic leukemia (APL) and provides a model for the development of novel therapies. Molecular alterations in the ligand-binding domain (LBD) of the PML/RARα fusion gene that characterizes APL constitute one mechanism of acquired resistance to ATRA. We identified missense mutations in PML/RARα from an additional ATRA-resistant patient at relapse and in a novel ATRA-resistant cell line, NB4-MRA1. These cause altered binding to ligand and transcriptional coregulators, leading to a dominant-negative block of transcription. These mutations are in regions of the LBD that appear to be mutational hot spots occurring repeatedly in ATRA-resistant APL patient cells. We evaluated whether histone deacetylase (HDAC) inhibition could overcome the effects of these mutations on ATRA-induced gene expression. Cotreatment with ATRA and TSA restoredRARβ gene expression in NB4-MRA1 cells, whose PML/RARα mutation is in helix 12 of the LBD, but not in an APL cell line harboring the patient-derived PML/RARα mutation, which was between helix 5 and 6. Furthermore, ATRA combined with TSA increases histone 4 acetylation on the RARβ promoter only in NB4-MRA1 cells. Consistent with these results, the combined treatment induces differentiation of NB4-MRA1 only. Thus, the ability of an HDAC inhibitor to restore ATRA sensitivity in resistant cells may depend on their specific molecular defects. The variety of PML/RARαmutations arising in ATRA-resistant patients begins to explain how APL patients in relapse may differ in response to transcription therapy with HDAC inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A decade of molecular biology of retinoic acid receptors
Chambon, P. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.9.8801176 · Cited by 2,889
Histone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884
A signature motif in transcriptional co-activators mediates binding to nuclear receptors
Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997) · Nature · doi:10.1038/42750 · Cited by 2,128
Identification of a receptor for the morphogen retinoic acid
Giguere, V., Ong, E. S., Segui, P., & Evans, R. M. (1987) · Nature · doi:10.1038/330624a0 · Cited by 1,965
Warrell, R. P., He, L.-Z., Richon, V., Calleja, E., & Pandolfi, P. P. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1621 · Cited by 502
Muindi, J., Frankel, Sr., Miller, W. J., Jakubowski, A., Scheinberg, D., Young, C., Dmitrovsky, E., & Warrell, R. J. (1992) · Blood · doi:10.1182/blood.v79.2.299.299 · Cited by 314
Self-citationDilworth, F. J., & Chambon, P. (2001) · Oncogene · doi:10.1038/sj.onc.1204329 · Cited by 269
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
“; furthermore, HDACi have been used in combination with retinoids to treat these disease”
BackgroundHistone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code
THIAGALINGAM, S., CHENG, K., LEE, H. J., MINEVA, N., THIAGALINGAM, A., & PONTE, J. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb05964.x · Cited by 700
Retinoic acid receptors: From molecular mechanisms to cancer therapy
di Masi, A., Leboffe, L., De Marinis, E., Pagano, F., Cicconi, L., Rochette-Egly, C., Lo-Coco, F., Ascenzi, P., & Nervi, C. (2015) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.12.003 · Cited by 403
Self-citationGRØNBÆK, K., HOTHER, C., & JONES, P. A. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_636.xml.x · Cited by 366
Dietary histone deacetylase inhibitors: From cells to mice to man
DASHWOOD, R., & HO, E. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.04.001 · Cited by 296
Metadata
- Authors
- Côté, S., Rosenauer, A., Bianchini, A., Seiter, K., Vandewiele, J., Nervi, C., & Miller, W. H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-10-01
- Volume
- 100
- Issue
- 7
- Pages
- 2586-2596
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2000877431
- Cited by
- 62
- References
- 7
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response to histone deacetylase inhibition of novel PML/RARα mutants detected in retinoic acid–resistant APL cells. https://app.cochat.ai/papers/10.1182/blood-2002-02-0614
- The paper
- Côté, S., Rosenauer, A., Bianchini, A., Seiter, K., Vandewiele, J., Nervi, C., & Miller, W. H. (2002). Response to histone deacetylase inhibition of novel PML/RARα mutants detected in retinoic acid–resistant APL cells. Blood. https://doi.org/10.1182/blood-2002-02-0614
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.